Sunshine Biopharma Inc. (NASDAQ:SBFM) saw its shares decline 21% on Thursday after the company disclosed it would implement a one-for-ten reverse stock split. The consolidation is scheduled to be effective at market open on June 1, 2026.
According to the filing, the reverse split will reduce the company’s issued and outstanding common shares from 21,236,346 to approximately 2,123,635. Sunshine Biopharma described the corporate action as a step to regain compliance with Nasdaq’s minimum bid price requirement for continued listing.
Sunshine Biopharma operates in the pharmaceutical sector and focuses on generic and specialty prescription medications. The company’s statement did not provide additional operational details or new financial figures beyond the share count adjustment and the stated regulatory objective of restoring compliance with Nasdaq rules.
The market reaction was immediate, with the stock price retreating sharply on the day the split was announced. The company set the split date as the opening of trading on June 1, 2026, at which point the reduced share count will become effective.
No further guidance, commentary on future corporate actions, or projections accompanied the announcement. The filing confines itself to the mechanics of the split and the compliance rationale tied to Nasdaq’s minimum bid price requirement for continued listing.
Contextual note - The disclosure specifies the exact pre- and post-split share counts and the intended effective date and time for the split. Beyond those items, the company did not expand on how the adjustment will affect outstanding options, warrants, or other equity-linked instruments.
This report is limited to the facts presented in the company notice: the reverse split terms, the stated reason tied to Nasdaq compliance, the effective timing, the before-and-after share counts, and the share price movement observed on Thursday.